Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In this study, we aimed to evaluate the prognostic impact of sarcopenia, five-item modified frailty index (mFI-5), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) in patients with oral cavity squamous cell carcinoma (OSCC) treated with adjuvant chemoradiotherapy (CRT) and their survival outcomes. We retrospectively enrolled 175 patients with OSCC undergoing adjuvant CRT between 2011 and 2018, who were divided into groups with ( = 112) and without ( = 63) sarcopenia. Logistic regression analysis and Cox proportional hazards models were used to determine prognostic factors for CRT-related toxicity, three-year overall survival (OS), and disease-free survival (DFS). Sarcopenia and high PLR were independently associated with CRT-induced anemia (CIA); advanced tumor stage was related to poor three-year OS. CRT and survival did not differ by mFI-5 and NLR. Our results indicate that sarcopenia and high PLR are significant predictors of adjuvant CRT, increasing toxicity outcomes and indicating worse short-term OS. Accurately identifying sarcopenia and high PLR in patients with OSCC is critical to help better select candidates for adjuvant CRT to improve their outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464994 | PMC |
| http://dx.doi.org/10.3390/jpm11090936 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment choices after endoscopic resection for pMM/SM1 esophageal squamous cell cancer: a retrospective study in China.
Surg Endosc
September 2025
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Endoscopy Center, Peking University Cancer Hospital & Institute, Haidian District, No. 52, Fucheng Road, Beijing, 100142, China.
Background: Treatment choices for patients with pathological muscularis mucosa/submucosal layer (pMM/SM1) esophageal squamous cell cancer (ESCC) after endoscopic resection (ER) are controversial.
Materials And Methods: A single-center retrospective study at Beijing Cancer Hospital in China was conducted. Between February 2012 and November 2023, we retrospectively recruited patients with pMM/SM1 ESCC who underwent ER with or without subsequent adjuvant therapy.
Comparison of postoperative adjuvant therapy for early-stage cervical cancer: A surveillance, epidemiology, and end results analysis.
J Cancer Res Ther
September 2025
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Sichuan, China.
Objectives: To compare the effects of different adjuvant treatments for different pathological types of early-stage cervical cancer post-surgery.
Materials And Methods: Patients with International Federation of Gynecology and Obstetrics (FIGO) stages I-II squamous cell carcinoma (SCC), adenocarcinoma (ADC), and adenosquamous carcinoma (ASC) who underwent hysterectomy and postoperative radiotherapy (RT) from 2004 to 2015 in the surveillance, epidemiology, and end results program database were analyzed. The clinicopathological characteristics and survival rates were compared.
Efficacy and safety of chemoradiotherapy versus chemotherapy for resectable gastric cancer: a systematic review and meta-analysis.
Ann Med Surg (Lond)
September 2025
University of Oklahoma Health Sciences Center, Oklahoma, United States.
Background: Gastric cancer is a leading cause of cancer-related deaths. Surgery combined with adjuvant treatments improves survival. This meta-analysis compares the efficacy of chemoradiotherapy (CRT) vs.
View Article and Find Full Text PDFEfficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer.
Cancer Lett
August 2025
Department of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China. Electronic address:
Locally advanced rectal cancer (LARC) remains challenging to treat due to high recurrence rates and limited therapeutic options, particularly for patients with high-risk features. This prospective, multicenter, single-arm, open-label phase 2 trial (ClinicalTrials.gov identifier: NCT05300269) evaluated the efficacy and safety of SHR-1701, a novel bifunctional fusion protein targeting both PD-L1 and TGF-β, in combination with neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME) for high-risk LARC.
View Article and Find Full Text PDFPredictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
Oral Oncol
August 2025
Department of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Background: Tumor tissue-modified viral (TTMV) HPV DNA is a sensitive, highly specific biomarker for human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPVOPC). We monitored the kinetics of TTMV responses to induction chemotherapy (IC) or induction chemoimmunotherapy (ICI) and analyzed the predictive implications for treatment outcomes.
Methods: Patients with locally advanced HPVOPC with high-risk features were treated with 3 cycles of IC (docetaxel-cisplatin-fluorouracil) or anti-PD1 ICI (docetaxel-cisplatin-Cemiplimab or docetaxel-cisplatin-Pembrolizumab).